conferenceseries.com 1286th Conference
7th International Conference on predictive, preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Scientific Tracks & Abstracts DAY 1
Personalized Medicine 2017
Page 31 Kanchan Mukhopadhyay, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Personalized treatment of ADHD probands: Potential role of dopaminergic transporter variants identified in Indians Kanchan Mukhopadhyay Manovikas Kendra, India
ack of inhibition, poor decision making and scholastic backwardness are major weaknesses observed in Attention Deficit LHyperactivity Disorder (ADHD) probands. Extensive research indicates contribution of neurotransmitters, chiefly dopamine (DA)/norepinephrine (NE) and hence, medications have been developed targeting these systems. However, due to broad variation in response, treatment is often discontinued. We analyzed role of DA/NE gene variants, DRD4 exon 3 VNTR, rs28363170, rs3785143, rs1611115 and rs4680, in treatment response. ADHD probands diagnosed following the diagnostic and statistical manual for mental disorders-IV were evaluated by the Conners’ Parent Rating Scale-revised (CPRS-R) to estimate the behavioural problems, inattention, hyperactivity and ADHD index. Peripheral blood collected from drug naïve ADHD probands, after obtaining informed written consent for participation, was used for genomic DNA isolation and analysis of gene variants. Probands were prescribed either Methylphenidate (MPH) or Atomoxetine (ATX) and post-treatment outcome was assessed using the CPRS-R. This pioneering study on Indian ADHD probands revealed more pronounced side effects after MPH treatment as compared to ATX. Gene variants showed correlation with MPH and ATX induced improvement. Quantitative trait analysis also revealed significant association between rs28363170/rs3785143 variants and response to medication. It may be inferred from the study that rs28363170 and rs3785143 could be major modulators for treatment outcome in this population; while MPH may be more beneficial in presence of rs28363170 10R and rs3785143 T variants, ATX treatment may provide relief in presence of rs28363170 9R and rs3785143 variants.
Biography Kanchan Mukhopadhyay has completed her PhD from Calcutta University and received Post-doctoral training at Tumour Laboratory, Tokyo, Japan. She is the Chief Scientist of Manovikas Biomedical Research and Diagnostic Centre, Kolkata a premier non-government organization in the eastern India for training and rehabilitation of intellectually challenged children. She has published more than 75 articles in reputed journals and had guided 11 graduate students leading to PhD.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 33 Mark R Miglarese, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
ADAPT biotargeting systemTM: A next generation poly-ligand profiling approach for precision medicine Mark R Miglarese Caris Life Sciences, USA
espite significant advances of precision medicine in oncology, the performance of predictive biomarkers and companion Ddiagnostics remain profoundly suboptimal. Clinical benefit from specific cancer therapies is determined by subtle differences in tumor system biology that are inherently difficult to access. Accordingly, highly multiplexed methods are required to evaluate these perturbations. We developed the ADAPT Biotargeting SystemTM which employs aptamer-based polyligand profiling to distinguish a wide range of complex yet subtle phenotypes including response to molecularly targeted therapy. We showed that the ADAPT Biotargeting SystemTM can distinguish tumor tissues from breast cancer patients who, either did or did not derive benefit from HER2-targeted trastuzumab-based regimens. Test performance was assessed by calculating AUC values from ROC curves and by generating Kaplan-Meier plots using Time To Next Therapy (TTNT) as a surrogate measure of clinical benefit. ADAPTTM test-positive patients showed improved clinical outcomes from trastuzumab-based treatment (median TTNT of 429 days versus 129 days for test-negative patients [n=61, HR=0.384, p=0.001]). Interestingly, the ADAPT test also identified patients who received significant clinical benefit from trastuzumab-based therapy despite having HER2-/ low scores by IHC (median TTNT of 421 days versus 199 days [n=23, HR=0.119, p=0.001] for chemotherapy alone). Thus, the ADAPT Biotargeting SystemTM has the potential to identify the patients who would benefit from trastuzumab-containing regimens despite standard HER2 testing suggesting otherwise. We are currently building a number of ADAPT assays to improve upon suboptimal predictive biomarkers currently used for a wide range of cancer therapies.
Biography Mark R Miglarese joined Caris Life Sciences as Vice President, Research & Development in August 2015. Prior to joining Caris, he founded OncoNex Consulting LLC and served as an Advisor and Interim Chief Scientific Officer for Cielo Therapeutics. Before that, he held various positions in the BioPharma Sector including Chief Scientific Officer at GeneCentric Diagnostics, Vice President of Oncology Translational and Clinical Science at OSI/Astellas, Assistant Director of Translational Research at Array BioPharma and Section Head in the Department of Cancer Research at Bayer HealthCare Pharmaceuticals. He has received his BS in Biology from Virginia Tech and earned his PhD from the Department of Microbiology and Immunology at the University of Virginia. He continued his Post-doctoral training at Pfizer Central Research and in the Department of Dermatology atYale University School of Medicine.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 34 Mark Rosenbloom, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Novel approach to pharmacogenomics: An electronic methodology utilizing predictive and known pharmacogenomics drug/gene interactions for clinical prescribing and patient monitoring Mark Rosenbloom PEPID, USA
ith over 50 important pharmacogenomic genes, each with multiple variants, and over 2,000 drugs, the potential drug/gene Winteractions estimates in the hundreds of thousands. It is impractical and virtually impossible to study all potential drug/ gene interactions, let alone incorporating drug/drug/gene and drug/gene/gene interactions. This extensive number of possible drug/gene interactions creates a challenge for implementing pharmacogenomics in practice. Now, through a methodology developed by the author, and based on pharmacokinetic and pharmacodynamic principles, clinicians can overcome this challenge by accessing known and predicted drug/gene interactions within seconds from a mobile phone, tablet, or computer. The author will demonstrate his recently developed drug/gene interactions tool, and a discussion of the methodology used to deliver known and predicted drug/gene, drug/drug/gene, and drug/gene/gene interactions. Designed to provide immediately actionable information to clinicians, the electronic methodology allows for better informed clinical prescription and patient monitoring decisions. The methodology is readily adaptable for hospital-wide systems and electronic medical records. The methodology will be discussed and examples will be given.
Biography Mark Rosenbloom is the Founder and CEO of PEPID LLC, recognized globally as the top developer and electronic provider of clinical decision support. His model of electronic delivery, streamlined concise medical information, built-in workflow and personal creation of thousands of point-of-care support tools now used in schools, hospitals and institutions in 159 countries worldwide. He is the Medical Director of LIFEFORCE Medical Institute in Chicago, Illinois. His education includes McGill University, Stanford University and Northwestern University’s Feinberg School of Medicine. He was the Recipient of the Dean’s AOA Research Award and the Sigmund S Winton Award in Biochemistry. He has served as Editor-in-Chief of “Your Health Magazine” and has published articles on drug interactions, age management, and low testosterone for men, BHRT, medical errors, and vitamin toxicity. He practiced at Northwestern Memorial Hospital achieving the rank of Adjunct Associate Professor of Medicine. Among his additional accomplishments, he is the Founder and past Chairman of the Unicorn Children's Foundation, an international non-profit organization annually raising millions of dollars and dedicated to promoting early identification and treatment of symptoms associated with ADHD, autism, bipolar, dyslexia and other learning disorders in children and young adults.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 35 Vladislav S Baranov, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Predictive medicine evolution Vladislav S Baranov D O Ott’s Institute of Obstetrics, Gynecology and Reproductology, Russia
redictive medicine (PM) as a kid from natural marriage of Human Genome and Medicine has now converted into quickly Pexpanded area of medical genetics. Main goal of PM may be attributed to early identification of persons, predisposed to sever complex diseases, before their obvious clinical manifestation and thus to their prediction, prevention, diagnostics and efficient personalized treatment. Progress of PM runs in parallel to spectacular achievements of human genome studies, advances of molecular technologies and their implementation. Started in 2000 as Predictive Preventive Personalized Medicine (3P-Medicine), it soon acquired its participatory trait and is now treated as 4P-medicine. After short period of recession in 2009-2012 provoked by “missing heritability”, dilemma time for the robust recovery of PM comes. New system genetics approach (SGA) paved the way to translational medicine, which obviously benefits stems from the complex analysis of common disorders. Brief review of European PPPM Association program of 30 years development and similar precision medicine program recently launched in the USA are presented. Thus for 20 years period, the PM has passed a long way from primitive genetic testing to systemic genetic analysis, from Genetic Pass suggested, as far as 2000 to Electronic Genetic Chart of Health predicted in 2015.
Biography Vladislav S Baranov graduated from the State Medical Institute in Lvov (Ukraine) and took Post-graduate courses and received a PhD degree in Saint-Petersburg (Russia) in 1976. He is the Chief of laboratory for prenatal diagnosis of inherited and inborn diseases at the Ott’s Institute of Obstetrics, Gynecology & Reproduction. He is interested in genetic and cytogenetic aspects of early development, gene testing of inherited predisposition to common disorders, personalized predictive medicine and gene therapy. He is a Professor, Corresponding Member of Russian Academy of Sciences, Honorary Scientist and Chief City Expert in Medical Genetics. He is the author and co-author of 29 books and over 400 scientific papers.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 36 Roland Valdes Jr, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Polypharmacy: A conundrum with a personalized laboratory medicine solution Roland Valdes Jr University of Louisville, USA
olypharmacy, the simultaneous consumption of multiple medications, is not presently considered a health condition Psuch as diabetes, high blood pressure or other chronic health syndromes. The use of multiple medications is growing at an alarming rate with reports documenting within a range of 12 and 22 prescriptions being used on average by individuals >50 years of age. The healthcare consequences range from drug-drug interactions, adverse drug events, prescribing cascades, chronic dependence and hospitalizations, all of which have significant health and economic consequences. Recent attention on precision medicine and personalizing therapeutics, along with advanced health informatics technology, provides the focus needed to manage this condition and avoid its complications. First, however, it is important to recognize polypharmacy as a healthcare condition or syndrome and how clinical laboratory diagnostics can play a role in addressing this national problem. Our discussion centers on the use of laboratory medicine diagnostics in preventing and managing pharmacotherapy with the use of combined pharmacogenetic testing and informatics tools designed to guide selection and dosing of medications. We urge establishing “polypharmacy” as a recognized healthcare syndrome that, if properly managed based on present technologies, can optimize clinical pharmacotherapy, provide a more precise personalized therapeutics and reduce economic burdens.
Biography Roland Valdes Jr is a Tenured Professor of Pathology and Laboratory Medicine at the University of Louisville’s School of Medicine where he has held the appointments of Distinguished University Scholar and Senior Vice-Chairman. He completed his PhD in Molecular Biophysics and completed Post-doctoral Training in Clinical Chemistry and Toxicology at the University of Virginia. He is nationally and internationally recognized as a Leader in advancing the profession of laboratory medicine; has served on Federal Regulatory Committees; as President of many National Professional Organizations; and, has received several distinguished scientist and professional recognition awards. He has authored more than 260 publications, holds several patents and is a pioneer in establishing the application of personalized and precision medicine via laboratory diagnostics.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 37 Michael Szardenings, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Epitope mapping of the human immunome directly from sera Michael Szardenings Fraunhofer Institute for Cell Therapy and Immunology, Germany
apping of antibody epitopes with standard peptide phage display is a common but not always really satisfying approach. MRefinement of library parameters for and application of deep sequencing in combination with a novel software analysis tool results in epitope information based on hundreds or more sequences presenting epitope/mimotope variations. The approach does not require more than two selection rounds and can be run in a relatively short time. Even when applied to sera, we observe significant enrichment of motifs of disease related antibody epitopes. These can all be retrieved from a single set of data obtained from a single phage display experiment with 1-2 µl serum. Due to the statistic approach based on short motifs of 3-4 amino acids structural motifs are also revealed. This detailed epitope/mimotope information can be used to generate peptides for various applications. This presentation will deal with the immunodiagnostic tools that can be generated from our data. We are able to generate arrays that enable for the first time an individualized analysis of a patient’s immune response even towards individual cross reactive proteins. In the case of allergies it allows us to determine potential cross reactivity to related species, since an individual epitope’s cross reactivity can be predicted from sequence alignments. The technology is today well enough established to approach larger projects like our present efforts to map most major food allergens or the identification of markers for virus serotypes.
Biography Michael Szardenings has a great personal interest in the advancement of combinatorial methods at the border line between Molecular Biology, Medicine and Chemistry and its exploration for pharmaceutical and medical relevant research. He has been working with enzyme inhibitors as well as membrane and nuclear receptors. His present research activities focus on the improvement of peptide phage display methods to establish novel cell type specific ligands and towards a better understanding of the immune response amongst others in allergies and infectious diseases. He studied Chemistry from Hamburg University with a Diploma Thesis on bioluminescent nucleic acid derivatives in 1985. Three years later, he received a Doctoral degree at the former German Biotechnology Center GBF (Braunschweig) for protein design of protease inhibitor hPSTI. After Post-doctoral years in protein crystallography and research on melanocortin receptors, he served as CSO and CBO for phage display and CRO companies between 1998 and 2009, when he was appointed as Group Leader of a continuously growing group at Fraunhofer IZI in Leipzig. He is now also heading a spin-off company in Leipzig for epitope mapping services.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 38 Shashi Amur, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Role for prognostic and predictive biomarkers in personalized medicine Shashi Amur FDA, USA
ultiple biomarkers have been used in drug development and clinical practice for a number of years. However, there has Mbeen confusion about the definitions and inconsistent use of key terms–including biomarkers and surrogates. Recently, an FDA-NIH Biomarker Working Group developed a glossary of terms and definitions to ensure consistency and clarity, termed BEST (Biomarkers, Endpoints, and other Tools), to advance scientific progress. The BEST glossary describes seven categories of biomarkers: diagnostic, prognostic, susceptibility/risk, predictive, pharmacodynamic/response, monitoring and safety biomarkers. Prognostic biomarker is defined as a biomarker used to identify likelihood of a clinical event, disease recurrence or progression in patients who have the disease or medical condition of interest and these biomarkers are often used as eligibility criteria in clinical trials to identify patients who are more likely to have clinical events or disease progression. An example is PIK3CA mutation status in women with HER2-positive metastatic breast cancer undergoing first line therapy. It has been reported that women with tumors harboring a PIK3CA mutation had worse progression-free survival compared with women with PIK3CA wild-type tumors regardless of treatment group. Predictive biomarker is defined as a biomarker used to identify individuals who are more likely than similar individuals without the biomarker to experience a favorable or unfavorable effect from exposure to a medical product or an environmental agent. These biomarkers can be used to identify individuals more likely to respond favorably or unfavorably to treatment. Examples include selection of newly diagnosed AML (acute myeloid leukemia) patients with FLT3 mutation positivity for treatment with midostaurin for increased likelihood of favorable response. The assays for predictive biomarkers are often co-developed with the therapeutics and become companion diagnostics where both the test and the drug would be used in the clinical management of the patient. The diagnostic tests being considered in this context may be used to identify patients most likely to respond to a drug, patients most likely to fail to respond to a drug, and/or patients most likely to exhibit adverse events that might contraindicate drug administration. Prognostic and predictive biomarkers can be integrated into drug development through the drug approval process as well as through qualification of the biomarkers through the Biomarker Qualification Program at CDER, FDA. These two categories of biomarkers can help identify the “right” sub-populations in clinical trials of therapeutics for a variety of diseases and be useful in clinical trial enrichment. The predictive biomarkers can additionally help tailor treatment appropriate for individual patients. Both approaches help advance the goal of personalized medicine.
Biography Shashi Amur has expertise in the area of disease biomarkers, biomarkers in drug development and pharmacogenomics. She joined FDA as a Senior Genomics Reviewer in the Office of Clinical Pharmacology (OCP) in 2005, served as the Scientific Lead of the Biomarker Qualification Program from 2012-2017 at the Office of Translational Sciences (OTS) and is currently working as a Scientific Advisor in OTS, CDER, FDA. Prior to joining FDA, she was the Associate Director of Assay Development at Neotropix, Inc. and Immune Tolerance Network. She received her PhD in Biochemistry from Indian Institute of Science, India and completed Post-doctoral Fellowship at Temple University and at University of California at Los Angeles, in Neurobiology and Neuromolecular Biology. She then joined Specialty Laboratories in Santa Monica, CA as a Research Scientist in the Molecular Biology division. Following this, she was a Senior Scientist at Applied Biosystems and gained expertise in application of DNA sequencing and PCR technologies.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 39 Darrell R Borger, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Multi-faceted approaches to cancer biomarker identification and testing in the precision medicine era Darrell R Borger Massachusetts General Hospital, USA
ecent advances in cancer treatment have centered on the development of targeted therapies that disrupt discrete intracellular Rcancer mechanisms and are essential in driving the underlying tumorigenic process. More recently, targeted cancer drugs have been developed against newly-discovered immune escape mechanisms in order to promote immune cell killing of tumor cells. While many of these therapies have significantly improved patient outcomes, rapid expansion of these therapies and the diversity of cancer targets pose many challenges for clinical evaluation and implementation. Of importance, it is the ability to identify new biomarkers that can accurately stratify patients to the most appropriate therapeutic drug and inform the development of effective combination therapy approaches. This is dependent on the ability to adopt new technologies, integrate various testing platforms, and utilize clinically-relevant patient sample cohorts in translational studies. This talk discusses the challenges and the approaches for diverse biomarker discovery as well as its clinical implementation in order to keep pace with rapidly evolving approaches to cancer treatment.
Biography Darrell R Borger obtained his PhD from the University of South Carolina, School of Medicine and completed his Post-doctoral studies at the Dana-Farber Cancer Institute where he also studied basic underlying cancer pathways. He currently serves as Director of the Biomarker Laboratory and Co-Director of the Immuno-Profiling Laboratory at the Massachusetts General Hospital where he serves a translational role through the pursuit of cancer biomarker discovery and clinical testing implementation.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 40 Manjit Singh Bal et al., J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Prostatic Specific Antigen (PSA): A predictive, diagnostic and prognostic biomarker in prostate cancer Manjit Singh Bal and Parul Kansa MM Medical College & Hospital, India
iomarkers are produced by cancer cells or other cells in response to cancer or some other conditions. These are also Bproduced by normal cells, however higher levels appear in malignancy. Most biomarkers are proteins though recently, patterns of gene expression and changes in DNA have also begun to be used as tumour markers. Various biomarkers are in clinical use, some are associated with only one type of cancer, whereas others are associated with two or more cancer types. No “universal” tumour marker has yet been found to detect any kind of cancer. Sometimes, non-cancerous conditions can also cause elevated levels of certain markers, so there are some limitations to their use. Cancer of Prostate is the second most common cause of cancer and the sixth leading cause of cancer death among men worldwide. In India also, accoding to reports of four PBCRs (Delhi, Kolkata, Nagpur and Thiruvananthpuram), prostate is the second leading site of cancer. Prostate-Specific Antigen (PSA), is elevated in prostate cancer. In 1994,PSA levels increase with the increasing Gleason's grade in prostatic cancer. We performed Tru-cut biopsies in 100 suspected cases of carcinoma of the prostate. Fifty nine biopsies were positive for adenocarcinoma prostate, 35 had benign prostate hyperplasia, one was prostatitis and five biopsies were inadequate. PSA levels were found high according to their Gleason's grades in carcinoma of prostate.
Biography Manjit Singh Bal has completed his MBBS and MD (Pathology) from GMC, Amritsar (India), and has a Fellowship (FICP) in Pathology; he retired after >37 years of govt. job including >31 years as Faculty and 17 years as Department Head. He is presently working as a Professor of Pathology at a private Medical College. His areas of research interest are as follows: Histopathology, Cytology and Oncopathology. He trained 115 Post-graduates and published 111 papers in Indian and overseas journals. He is an Editorial Board Member and reviewer for reputed journals. He is a regular Columnist of health articles in Punjabi for Indian and overseas news papers. He has authored 11 books in Punjabi, English and Hindi on health topics and literary.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 41 conferenceseries.com 1286th Conference
7th International Conference on predictive, preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Workshop DAY 1
Personalized Medicine 2017
Page 43 K K Jain, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
K K Jain Jain PharmaBiotech, Switzerland
Application of principles of personalized medicine for cancer management ancer is the most important area for application of personalized medicine, also called precision medicine. This workshop will Cdeal with the basic principles of personalized oncology. Cancer is a multifactorial complex disease. Variations in behaviors of cancer of the same histological type, from one patient to another are taken into consideration in addition to variations among patients. Cancer varies both genetically and phenotypically between patients who may have the identical type and stage of cancer. Epigenetic factors also play a role. Each person's cancer is as unique as his or her fingerprint. Personalization of cancer therapies is based on a better understanding of the disease at the molecular level. Molecular diagnostics, molecular imaging, sequencing and monitoring of gene expression by microarrays are important technologies for this purpose. Integration of information gained from various ‘omic’ technologies such as genomics, proteomics, metabolomics, is important in developing personalized approaches. Identification of cancer biomarkers that can enable pre-symptomatic diagnosis, stratification of cancer, assessment of its progression, evaluation of patient response to therapy, and the identification of recurrences. Study of cancer pathways is providing new targets for anticancer drugs. Among the available therapeutics, matching of the right drug to the right type of cancer and appropriate combination of various options required for a complex disease is important. Improvement of drug formulation and delivery is facilitated by nanobiotechnology. Anticancer medicines can be targeted to the tumor and spare the normal tissues to reduce systemic toxicity.
Biography K K Jain is a Neurosurgeon with his career in North America. After retirement from Neurosurgery, he started a second career in Pharmaceutical Medicine and Biotechnology in Switzerland. Currently, he is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. He is developing personalized medicine since 1998, and wrote the first monograph on this topic, which evolved into a textbook and the 2nd edition was published by Springer in 2015. His 465 publications include 27 books (5 as Editor and 22 as the Author), e.g., “Applications of Biotechnology in Oncology” (Springer, 2014) as the sole author and “Nanooncology: Clinics Lab Med” (Elsevier, 2012). Editorial Board Memberships of journals including “Technology in Cancer Research & Treatment” and “Nanomedicine”.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN:2153-0645 JPP, an open access journal October 05-06, 2017
Page 44 conferenceseries.com 1286th Conference
7th International Conference on predictive, preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Scientific Tracks & Abstracts DAY 2
Personalized Medicine 2017
Page 51 Steven A Feyrer-Melk, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Personalized care, lifestyle medicine, behavioral science and technology: The right fit for any practice model Steven A Feyrer-Melk Optimal Heart Attack & Stroke Prevention Center, USA
odifiable personal lifestyle factors play significant and interconnected roles in predictive, preventive and personalized Mpatient optimal health. Leveraging available cutting-edge Technology and Behavioral science models can maximize outcomes in a Personalized Care Model. This session will help medical program developers and practitioners learn how to seamlessly incorporate and effectively use the proper practice-matched technology. The focus will be on understanding behavioral science as a powerful component of personalized care, identifying the best technologies for the practice, wearable technology, wireless health technology, health apps, and practice platform technologies.
Biography Steven A Feyrer-Melk has developed a unique and practical background in Lifestyle Medicine for over 25 years, allowing him to effectively leverage technology and behavioral science to enhance personalized care. His extensive work with healthcare professionals and patients is grounded in proven health and lifestyle medicine principles, making him a thought leader in the field. He serves as the Director of Lifestyle Medicine at the Optimal Heart Attack & Stroke Prevention Center, the Chief Science Officer for a Med-Tech company (Nudge, LLC) and is a valued Consultant and Speaker. He received his PhD in Exercise Science & Wellness at Arizona State University under the direct guidance of Charles Corbin. He did his MEd in Human Performance at Bowling Green State University under Richard Bowers.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 53 Shanrong Zhao, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Isoform quantification in RNA sequencing: Challenges and applications Shanrong Zhao Pfizer Worldwide Research & Development, USA
ue to alternative splicing, over 90% of human genes have multiple transcript isoforms. Isoforms of the same gene can play Ddistinct or even opposite biological roles. For instance, gene TP53 has an important role in oncology and different cancer types show different expression profiles of its transcript isoforms. Therefore, it is tempting to quantify RNA-Seq experiments at transcript level, rather than at the gene level. However, estimating the expression of individual isoform is intrinsically challenging because different isoforms of a gene usually have a high proportion of genomic overlap. Recently, a number of tools have been developed for RNA-Seq isoform quantification, including RSEM, Cufflinks, eXpress, Tigar2, Kallisto, Salmon and Sailfish. We performed a systematic evaluation on those methods using both simulated dataset and UHRR and HBRR, and furthermore investigated the impact of gene/isoform structures on the accuracy of isoform quantification. Besides, the library size and relative abundance of different isoforms also influence the quantification results. We determined why RNA-Seq is unable to detect less abundant TP53 transcripts and discussed its implications for the general interpretation of RNA-Seq data.
Biography Shanrong Zhao is working as the Director, Computational Biologist and Bioinformaticist at Pfizer Inc. He has more than 20 years experience in computer science, statistics, genetics and computational biology. He also has deep scientific knowledge in immunology, autoimmune diseases, antibody design and biomarker discovery. He has demonstrated track of records in scientific initiative, innovation, and leadership, including 4 patents, over 20 peer-reviewed publications, and 20 invited talks at international meetings. A recognized Pioneer in the field of RNA-Seq, big data analysis and cloud computing. He is further enthusiastic about using NGS technology, computational approaches and informatics systems to drive drug discovery and biological research.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 54 Natalia Malara, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Implications of circulating tumor cell for precision medicine in intracranial tumors Natalia Malara Magna Graecia University, Italy
he immunotherapy in cancer is based on the ancient concept of activating an effective immune-mediated reaction directly Tagainst tumour cells. How to efficiently activate the immune system in this direction is still a challenge. In fact, despite the rapid increase of knowledge in oncology, it has contributed to improve immunotherapeutic protocols, some issues still remain unresolved. Three key points represent the main challenges causing vaccine resistance: 1. Continuous dynamic changes of cancer tissues determine intrinsic tumour cell alterations; 2. Adjustments in the tumour microenvironment; 3. Low immune recognition against cancer cells. The tumor during its progression depends on the possibility to analyse cancer cells in real time. Often, the clinicians do not have sources of available tumour cells. In fact, the biopsy of the tumour tissue cannot be repeated many times, for systemic and local complications of the patient. On the other hand, the development of vaccine resistance depends on the heterogeneity of tumor tissue. The cancer heterogeneity represents a limit in the design and application of immunotherapy adopting specific immunogenic protein. The CTCs represent the cancer cell population released in the blood stream and can be considered like a cellular “summary” of the systemic cancer disease. Recent studies report standardized methodology to collect for short-time in vitro expanded CTCs. The protocol, making available the cancer cells, without modifying their heterogeneity, provides interesting solutions to overcome the degree of immune tolerance and on the other hand, to reduce the autoimmune spiral triggered by the cryptic epitopes.
Biography Natalia Malara is a Medical Oncologist with competence in translational medicine, nanotechnology, toxicology in oncologic and cardiovascular field. She conducts clinical and laboratory investigations focusing her attention on circulating tumor and endothelial cells. She acquired a solid experience in nano-biotechnology techniques with translational approach in medicine collaborating with Bionem group guided by Prof. Di Fabrizio. She began her collaboration with Prof. Mollace in July 2009, and since then her research activities are also focused on the project of pre-clinical model finalized to improve pharmacological applications in clinical.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 55 Somi Kim Cho, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Therapeutic implication of the phytochemicals in human gastric cancer cells Somi Kim Cho Jeju National University, Republic of Korea
he cysteine-rich angiogenic inducer 61 (CYR61), an extracellular matrix-associated protein, is involved in survival, Ttumorigenesis, and drug resistance. There is an increasing demand for developing agents that target CYR61. Hence, we study the effects of flavones against CYR61-overexpressing human gastric adenocarcinoma AGS (AGS-CYR61) cells. Quercetin down-regulates CYR61 and concomitantly decreases in the levels of MRP1 (Multidrug Resistance-Associated Protein-1) and nuclear factor NF-kappa B (κB) p65 sub-unit, reverses multidrug resistance, and inhibits colony formation in AGS-CYR61 cells.
AGS-CYR61 cells treated with quercetin at sub IC50 over a range of 5-FU or ADR concentrations manifested strong synergistic effects with these two drugs. Our results demonstrate that CYR61 is a potential regulator of ABC transporters and quercetin can be the novel agent that improves the efficacy of anticancer drugs by down-regulating CYR61 and ABC transporters. Histone deacetylase 6 (HDAC6) is a unique cytoplasmic enzyme which contributes to malignant progression in various cancer. We found that compound D inhibits HDAC6 activity, increases acetylated α-tubulin, reduces the level of β-catenin, and suppresses cell proliferation. Increase of α-tubulin acetylation by compound D resulted in tubulin polymerization, and consequently, induced aberrant mitosis. Moreover, treatment with high concentrations of compound D induces cell death by mitotic catastrophe, whereas low concentration of compound D induces senescence with upregulation of p21 and Rb, and increase in the phosphorylation of mTOR and the β-galactosidase activity. Therefore, compound D can also be considered as a promising new candidate for anti-cancer drug development.
Biography Somi Kim Cho is currently working in the Department of Biotechnology, Jeju National University, Korea. She has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. She has extended her valuable service towards the scientific community with her extensive research work.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 56 Kamalidin Sharipov, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
The role of omiks technology in the formation of personalized medicine and research of metallom Kamalidin Sharipov Asfendiyarov Kazakh National Medical University, Kazakhstan
edicine of the XXI century is inseparably linked and more often uses data of omiks technologies for the diagnosis and Mtreatment of different diseases. The using of multi omics technology in biomedicine contributes to the formation of innovative concept of individual approach to each patient, i.e. personalized medicine. In the development of personalized medicine, we not only use genomic technologies and genotyping, but other omiks technologies such as metabolome research, methabonome, metallom, etc. Metallom – is a quantitative measurement of metallom components (products of interaction of ionic and atomic forms of metals with endogenous ligands). Nowadays the role of many chemical elements is established in processes of growth, differentiation, regeneration, cell apoptosis and necrosis, as well as, in the pathogenesis of some diseases, which is accompanied by significant changes in the element status of body. In our research’s, we determined the content of metallom component in more than 25 chemical elements including, vitally important in people's hair and improved personalized approach to each patient based on identified regularities of quantitative changes in the body. As would be expected element gramma of examinees people were mostly in the normal range, and some deviations had multidirectional nature. Deviation of essential and trace elements from norm was more specific (for such elements as cobalt, zinc and copper downward and for silicon upward, that might indicate or lead to certain orphan diseases in the future or disturbing signal comprehensive study and personalized approach). Thus, we can conclude that a personalized approach to increase the effectiveness of treatment for each patient with myltuomics technology and specific therapeutic effects, reduces the risk of unwanted side effects, precludes mistake assignment ineffective drugs, reduces the cost of treatment and develops predictive and preventive medicine.
Biography Kamalidin Sharipov graduated from the Pharmacy Faculty of Almaty State Medical Institute in the year 1990. He completed dissertation of Chemical Science in Institute of Chemical Science of Kazakhstan Republic in the year 1994. He completed Doctor’s dissertation of Biological Science in the year 2003 and from 2004, he is a Full Professor. He has published more than 100 articles in reputed journals and has given presentations on scientific reports in different international conferences and seminars (Russia, France, Germany and China). He is the Editorial Board Member of 2 journals: “Trace Elements in Medicine” Moscow, Russia and “Actual Problems Transport Medicine” Odessa, Ukraine.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 57 Moonjae Cho, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
The synergy effect of TMF and Glycitin on wound repair Moonjae Cho Jeju National University, Republic of Korea
eratinocyte-fibroblast interactions are critical for skin repair after injury. During the proliferative phase of wound healing, Kproliferation, migration and differentiation of these cells are the major mechanisms leading to tissue remodeling. We have previously reported that glycitin, a major soy isoflavone, stimulate dermal fibroblast proliferation; and the phytochemical, 4',6,7-Trimethoxyisoflavone (TMF), and induce migration of HaCaT keratinocyte cells. We therefore investigated whether these compounds display synergistic effects on skin cells during wound healing in-vitro and in-vivo. Co-treatment with TMF and glycitin synergistically promotes the proliferation and migration of both keratinocytes and dermal fibroblasts, with a 1:1 ratio of these compounds showing the greatest efficacy in our co-culture system. This keratinocyte-fibroblast interaction occurred via the secretion of TGF-β, and the induction of differentiation and proliferation was confirmed in both indirect and direct co-culture assays. In an excisional and burn wound animal model, mice treated with a 1:1 ratio of TMF and glycitin showed faster wound closure, regeneration and scar reduction than even the positive control drug. These data indicate that two isoflavones, TMF and glycitin, act synergistically to promote wound healing and anti-scarring and could potentially be developed together as a bioactive therapeutic for wound treatment.
Biography Moonjae Cho is currently working in the Department of Biotechnology in Jeju National University. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 58 R Y Abdullaev, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Ultrasonic characteristics of herniated intervertebral сervical discs in older children R Y Abdullaev Kharkiv Medical Academy of Postgraduate Education, Ukraine
Aim: To study the semiotics of the herniated intervertebral disks (IVD) of the cervical spine in older children using ultrasonography (US). Materials & Methods: The study included the results of ultrasound examination of 19 children with degenerative changes of the IVD with violation of the integrity of the fibrous ring (FR) and involvement of the elements of the vertebral canal (VC) in the pathological process. In total, 114 IVD were examined, of which changes were detected in 61 (53.5%) disks. US was conducted at the level of disks C2-C3, C3-C4, C4-C5, C5-C6, C6-C7, C7-Th1. Diagnosis of hernia of the IVD was based on the evaluation of the structure of the pulp nucleus (PN) and FR, registration of the FR rupture, narrowing of the PN and radicular canals. Results: Herniated discs were detected in children aged 16-18 years. Hernia is diagnosed in 19 (16.7%) disks. The rupture occurred in the posterior part of the discs, the free fragment of the PI ripping the thin sheet of the posterior longitudinal ligament, got into the epidural space, being located next to the veins of the epidural plexus. In 8 (42.1%) cases, hernia was formed at the level of C5-C6, in 6 (31.6%) - at the level of C4-C5, in 3 (15.8%) - at the level of C2-C3 and in 2 ( 10.5%) of cases at the level of C6-C7. The most frequently recorded paramedian hernia - in 12 (63.2%), then the median - in 5 (26.3%) cases and less often in the posterolateral - in 2 (10.5%) cases. The greatest decrease in the sagittal size of the PN was observed with the median size, and the cross-sectional area with the paramedian hernia (fig 1, 2) Conclusions: Ultrasound examination is an alternative method of diagnosing herniated intervertebral cervical discs in older children that allows determining the form and level of localization of the degenerative process.
Biography R Y Abdullaev is currently working in the Department of Clinical Trials, Hematology, Radiology in Kharkiv Medical Academy of Postgraduate Education. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 59 Xiaowu Gai, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Implementation of a hybrid informatics solution for a large personalized medicine program Xiaowu Gai Children's Hospital Los Angeles, USA
he bioinformatics needs a large personalized or precision medicine program which exemplify the 3Vs of big data challenges: Tvolume, variety and velocity. In the center of personalized medicine at Children's Hospital Los Angeles, we offer a variety of genomics-based somatic and germline genetic tests (single-gene, gene-panel, whole-exome, whole-genome, chromosomal microarray) for a large number of pediatric patients with either cancers or constitutional disorders. To address the needs and challenges, we implemented a hybrid informatics solution in terms of both the IT infrastructure and the bioinformatics tools. First of all, we employed an on-premise High-Performance Computing Cluster (HPCC) to address the mission-critical computing needs, established the parallel IT infrastucture in AWS cloud for redundancy, bursting nature of our computing needs and cost-effectiveness. Similarly, while implementing a phenotype-driven analytic platform for these genomics-based tests, we used a combination of open-source and custom software tools, striving to provide the most cutting-edge bioinformatics solution at an academic medical center. Examples of our custom solution includes 1) a cloud- and web-based variant store using the OpenCGA package that we developed in collaboration with the Genomics England Project team for storing and analyzing somatic and germline variants from whole-exome sequencing and whole-genome sequencing of thousdands of patients, 2) an algorithm for computational phasing two candidate heterozygous variants in a single gene and for improved clinical diagnosis rate of recessive disorders therefore, and 3) an NGS coverage analysis algorithm that is 10 times more efficient than the most popular similar tools, namely SAMtools and Sambamba.
Biography Xiaowu Gai serves as the Director of Bioinformatics in the Center for Personalized Medicine at Children's Hospital Los Angeles (CHLA). He is an Associate Professor of Clinical Pathology at the Keck School of Medicine, University of Southern California. Before joining CHLA, he was the Director of Bioinformatics and Associate Director of the Ocular Genomics Institute in the Department of Ophthalmology at Harvard Medical School & Massachusetts Eye and Ear Infirmary, Boston. Prior to that, he served as the Director of Biomedical Informatics at Loyola University Chicago Stritch School of Medicine.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 60 Candida Fratazzi, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Reinventing the clinical trials process: The SCIO concept meets Personalized Medicine needs Candida Fratazzi BCR Consulting Cambridge, USA
recision medicine identifies the evolving field holding the promise to transform our health care system, which consumes Palmost $3 trillion a year. Clinical trials are at the heart of the drug development process. They represent a significant proportion of the total cost and effectively define the critical path to a regulatory submission. Even the most simple study costs over $1m and in the later stages of the development phase, they can cost hundreds of millions of dollars and take several years to complete. Historically, the clinical trial process had been designed to develop therapeutics for the average patient. This one-size-fits-all approach has demonstrated not effective, as demonstrated by the rising cost and low success rate of clinical trials as well as the percentage of non-responder patients in clinical trials. Precision medicine is the tailoring of medical treatments to the individual characteristics of each patient, and the ability to classify individuals into subpopulations based on their susceptibility to a particular disease or their responses to a specific treatment. The development of precision therapies is closely associated with subpopulations defined by biomarkers. The design of clinical trials for these subpopulations represents a challenge from the perspective of population size, determination of response thresholds and co-development of diagnostic assays to support novel therapies. A fundamental shift in perspective and a willingness to challenge the clinical trial process is required. The SCIO concept solution provides innovation to the trial process in which new technologies find the ideal background to be developed and applied.
Biography Candida Fratazzi devised the concept of SCIO and Founded the first SCIO BBCR Consulting in 2009, with the objective of actively contributing to innovation in the clinical process. She acts as a Consultant to drug and device companies, and investors. She is a renowned Immunologist; contributed to the registration of four drugs. She is Recipient of 2013, 2014 and 2015 Best Pharmaceutical Consultant, Member of Advisory Board and Board of Directors. She acts as Invited speaker and Chairman at international conferences. She received her early training at the John Hopkins University and Harvard University in the USA, and at Imperial College in London.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 61 conferenceseries.com 1286th Conference
7th International Conference on predictive, preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Young Researchers Forum DAY 2
Personalized Medicine 2017
Page 63 Livija Sušić et al., J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Arrhythmogenic right ventricular cardiomyopathy with multiple thrombi – Case report Livija Sušić1, 2, Vedrana Baraban2, 3, Josip Vincelj2, 4, Lana Maričić 2, 3, Miroslav Sikora1, 2, Jasmina Ćatić 2, 4 and Robert Blažeković2, 4 1Health Centre Osijek, Croatia 2J J Strossmayer University Osijek, Croatia 3University Hospital Centre, Osijek, Croatia 4University Hospital Dubrava, Zagreb, Croatia
rrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy commonly transmitted as Aan autosomal dominant trait, characterized by incomplete penetrance and variable expressivity. So far 13 disease genes have been identified, responsible for approximately 60% of all ARVC cases. The pathological consists of a dystrophy of right ventricle (RV) myocardium with fibro-fatty replacement which leads to RV aneurysms dilatation, providing a supstrate for life-treatening arrhythmias. The course of the disease is divided into four main stages: Subclinical, overt electrical, RV dysfunctional and biventricular late stage. Dilatation of the RV and global or focal wall motion abnormalities are supposed to increase the risk of thrombus formation. It is estimated that annual thromboembolic incidence is 0,5/100 patients, which is extremely rare considering the prevalence of disease being between 1 per 2000 and 1 per 5000 inhabitants. We present the case of 61 year old female patient with multiple thrombi in a cavity of RV who had a combination of ARVC and hereditary trombophilia (homozygous mutation on 5GPAI-1 allele). It is very rare combination and diagnostic challenge for us. Considering that diagnostic protocol went retrograde from rare complication according to cause and that it included anamnesis, laboratory tests, interpretation of ECG and holter ECG monitoring, multimodal imaging methods (TTE, TEE, MRI, multislice CT, PET CT, coronarography), surgical procedure with extirpation of multiple RV masses and pathohistological analysis, and molecular markers of inherited thrombophilia, we believe that this is phenomenal example of the application of personalized medicine into practice.
Biography Livija Sušić has completed her Faculty of Medicine from J J Strossmayer University, Osijek, Croatia. She is an Internist and Head of Specialist Consultation Department in Health Centre Osijek. She is also a Post-graduate student on J J Strossmayer University, Faculty of Medicine. She is at the beginning of her scientific career and published 4 papers till now.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 65 Seyedeh Afrooz Azimi, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Epigenetic in lung cancer Seyedeh Afrooz Azimi Mashhad University, Iran
he concepts of personalized medicine can be applied to new and transformative approaches in health care. Epigenetic Tis based on the dynamics of system biology and uses predictive tools to evaluate health risks and to design personalized health plans to help patients mitigate risks, prevent disease and to treat it with precision when it occurs. Every person has a unique variation of the human genome. Although most of the variation between individuals has no effect on health, an individual's health stems from genetic variation with behaviors and influences from the environment and epignetic can also be used to predict a person’s risk for a particular disease and more effective than one or even several genes. One of the largest issues is the fear and potential consequences for patients who are predisposed after genetic testing or found to be non-responsive towards certain treatments. This includes the nutrition, life style, job effects on patients due to genetic testing results. The right of family members who do not directly consent is another issue, considering that genetic predispositions and risks are inheritable. The implications for certain ethnic groups and presence of a common allele would also have to be considered. We received the whole information of patients with NSCLC. According to this survey, that NSCLC is a multi factorial disease and related to epigenetic, if we want to predict the risks of the disease, we need to know more about the effects, life style and the personal behaviors more than the genetic and directly exposed parameters. Maybe in future, we can say there is difference for description of disease based on personal life and epigenetic.
Biography Seyedeh Afrooz Azimi has completed his PhD degree from Mashhad Medical University. She is the Quality Manager in Atieh Hospital in Tehran. She researches on NSCLC Diagnostic Biomarkers in Dr. Masih Daneshvari Hospital, Lung Center of Shahid Beheshti Medical University and she cooperates to published texts in scientific and research center.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 66 Hala Fakhro, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Clinical decision support system to reduce the incidences of venous thromboembolism among patients treated with combined oral contraceptives according to personalized medicine approach Hala Fakhro University of Aleppo, Syria
Background: The implementation of evidence-based clinical decision support system has shown the potential to increase the safety, quality and the efficiency of health care services and the patient outcomes. This research investigated the possibility of developing the Clinical Decision Support System Regarding Prescribing Combined Oral Contraceptives (CDSS-COCs) to decrease Venous Thromboembolism (VTE) incidences among the users of Combined Oral Contraceptives (COCs) based on the guidelines from World Health Organisation (WHO), UK Medical Eligibility Criteria For Contraceptive use (UKMEC), and Centres for Disease Control and Prevention in America (CDC), and further evaluated with specific guidelines. This research also checked the feasibility of implementing the proposed system in the Health Information System (HIS) in Finland. Methodology: Narrative literature review was followed by using Google Scholar, PubMed, Mendeley Software, Tallinn University of Technology databases and the Tampere University of Technology databases. Also, quantitative and qualitative methods were employed by conducting deep semi-structured interviews with application developer and expert clinician, and conducting an online and paper-based questionnaire among the expected future users. Results: This research managed to develop the proposed system CDSS-COCs by considering the existence of these six risk factors “age ≥35 years old, body mass index (BMI)>25 kg/m2, smoker, personal history of VTE, family history of VTE and the genetic factor V Leiden mutation” before describing COCs. This consideration will decrease the incidences of VTE by providing the user with the alternative treatment suggestion in case the risk exists. Also, this research managed to examine the reliability and the usability of the proposed system from different aspects: Technical, user, and partially from the clinical aspect. The applicability of the proposed system is restricted to implement the proposed algorithm instantly due to the missing structured data in EHR: The smoking and family history factors. Moreover, the genetic factor V Leiden mutation is not available in all patients, because there is no official policy in Finland that requires screening this genetic factor except in very specific cases. Conclusion: This proposal has been designed to be a practical tool to provide clinical decision makers with a direct consultation based on the electronic patients data which are retrieved from the digitalized data repository. Therefore, the proposed system will provide clinicians with the proper hormonal treatment suggestion based on personalized medicine approach.
Biography Hala Fakhro is currently working in the University of Aleppo. She has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. She has extended her valuable service towards the scientific community with her extensive research work.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 67 conferenceseries.com 1286th Conference
7th International Conference on predictive, preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
workshop DAY 2
Personalized Medicine 2017
Page 69 Kevin John Fowler, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Kevin John Fowler Kidney Health Initiative, USA
The need for precision medicine in kidney transplantation ince the first successful kidney transplant between the Herrick twins in 1954, the lives of thousands of patients have been Ssaved and transformed through kidney transplantation. While innovation has continued in kidney transplantation, long term outcomes have not changed. In the United States, at 10 years post-transplant, 50% of kidney transplant recipients have lost their transplanted kidney. The lack of change in long term outcomes is partially caused by the increased occurrence of cancer, infections and metabolic syndrome found among kidney transplant recipients compared to the general population. The increases in these post-transplant diseases is caused by the organ rejection medications that recipeints take for life. Beyond the impact on post-transplant mortality, the medications also dimish quality of life. The current post-transplant monitoring test is serum creatinine function. This test is limited in its ability to determine the appropriate immunosuprressant dose, and determine whether the patient is either under immunosuppressed or over immunosupressed. Besides the lack of specificity, the serum creatine test lacks the ability to predict future events such as acute and chronic rejection. Essentially, transplant nephrologists are forced to practice reactive medicine rather than proactive medicine. There is a need for a post-transplant monitoring test that provides specific and accurate information that will enable nephrologists to prescribe the appropriate dose which will reduce post-transplant cancer, infections, improve qulaity of etc. and prevent the development of acute and chronic rejection.
Biography Kevin John Fowler is a Healthcare Executive with over 30 years of Life Sciences experience in Pharmaceutical Organizations both commercial and R&D. During his career, he has demonstrated leadership in sales management, training, public affairs, global marketing, patient advocacy and patient marketing. He formed his own patient advocacy and patient engagement consulting business in 2014, “The Voice of the Patient, Inc.’’.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 70 conferenceseries.com 1286th Conference
7th International Conference on predictive, preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Video Presentation DAY 2
Personalized Medicine 2017
Page 71 Maria Voyatzi, J Pharmacogenomics Pharmacoproteomics 2017, 8:4 (Suppl) conferenceseries.com DOI: 10.4172/2153-0645-C1-018 7th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics October 05-06, 2017 Chicago, USA
Efficacy of lasers on pigmentary lesions, telangiectasias, hemangiomas and rejuvenation Maria Voyatzi Dermatologist, Greece
ur purpose was to study the efficacy of the Alexandrite laser and the fractional laser when treating pigmentary lesions, the Oefficacy of the NdYAG laser (1064 nm) when treating telangiectasias and hemangiomas and the efficacy of the NdYAG laser and fractional laser on rejuvenation. We used the data from our private office from the past five years (2011-2015). We treated 1000 patients with freckles with Alexandrite laser, 200 patients with melasma with fractional laser, 100 patients with post-inflammatory hyperpigmentation with Alexandrite laser and 60 patients with post-inflammatory hyperpigmentation with fractional laser. We also studied the side effects of the therapies. Alexandrite laser had excellent results on freckles, while the combination of chemical peels and fractional laser was satisfactory for the treatment of melasma. Post inflammatory hyperpigmentation had an intermediate response. The recurrence rates were higher in melasma and the side effects were generally minimal. We also treated 500 patients with telengiectasias and 300 patients with hemangiomas with NdYAG laser. As far as telangiectasias were concerned, the results were much better when the face was treated. In contrast, the recurrence rates were much higher when the legs were treated. The results were impressive in almost all cases of cherry hemangiomas. The combination of NdYAG lasers and fractional lasers on a monthly basis had satisfactory results in rejuvenation.
Biography Maria Voyatzi completed her PhD from the Aristotle University of Thessaloniki, Greece and Post-doctoral studies from the Hospital of Dermatological and Venereological Diseases of Thessaloniki, State Clinic. She has published more than 15 papers in reputed journals and participated in many Hellenic, European and world congresses.
Notes:
Pharmacogenomics Pharmacoproteomics Personalized Medicine 2017 Volume 8, Issue 4 (Suppl) ISSN: 2153-0645 JPP, an open access journal October 05-06, 2017
Page 72